Apigenin Attenuates Lipopolysaccharide-Induced Endothelial Activation and Injury-Associated Phenotypes in Human Umbilical Vein Endothelial Cells
- 1Reproductive Medicine Center, Jieyang People’s Hospital, Jieyang Cancer Center, Jieyang, Guangdong, People’s Republic of China
- 2Department of Urology, Jieyang People’s Hospital, Jieyang Cancer Center, Jieyang, Guangdong, People’s Republic of China
- 3Department of Obstetrics and Gynecology, Jieyang People’s Hospital, Jieyang Cancer Center, Jieyang, Guangdong, People’s Republic of China
Abstract
Background: Sepsis represents a severe challenge in critical‑care medicine. Protecting endothelial function and alleviating microvascular inflammation and oxidative stress help reduce sepsis‑associated mortality. Apigenin, a natural flavonoid, exerts anti‑inflammatory and anti‑oxidant effects; its mechanisms against endothelial injury relevant to sepsis remain unclear.
Purpose: This study combined computational biology and in‑vitro assays to explore potential targets of apigenin against lipopolysaccharide‑triggered endothelial dysfunction.
Methods: Network pharmacology was performed for target screening followed by GO and KEGG enrichment. Transcriptomic profiles were analyzed. Molecular docking and 100‑ns molecular dynamics simulations predicted apigenin‑protein interactions. An LPS‑stimulated HUVECs injury model was established. qRT-PCR, ELISA, flow cytometry and fluorescent probes were used to evaluate inflammation, apoptosis, reactive oxygen species and monocyte adhesion.
Results: A total of 104 intersecting targets were identified. AKT1, HSP90AA1, EGFR, ESR1 and HIF1A were potential core candidates, with PI3K‑Akt, TNF and HIF‑1 signaling possibly involved. Simulations predicted relatively stable apigenin‑protein complexes. At 40 μM, apigenin mitigated LPS‑provoked inflammatory response, oxidative stress, apoptosis and monocyte adhesion in HUVECs.
Conclusion: Apigenin protects HUVECs from LPS‑induced endothelial injury possibly via multi‑target and multi‑pathway patterns. This study provides preliminary computational and in vitro evidence for further investigation of apigenin against LPS-triggered endothelial injury, with potential implications for sepsis-associated vascular damage that requires further in vivo validation.
Related
- IGFBP2 attenuates high glucose-induced endothelial dysfunction through PI3K/Akt/eNOS pathway activation
- Sepsis-associated endothelial dysfunction: clinical phenotypes, biomarkers, bedside evidence, and translational implications
- AICAR attenuates senescence-associated phenotypic remodeling of liver sinusoidal endothelial cells via the AMPK–SIRT1/p53 axis in CCl₄-induced liver fibrosis
- GPR84 inhibition attenuates sepsis-associated acute lung injury and preserves pulmonary endothelial barrier function associated with YY1 suppression
- Delta-8-tetrahydrocannabinol attenuates colitis and is associated with changes in myeloid cell phenotypes and let-7a-5p expression
BibTeX
@article{wen2026apigenin,
title = {{Apigenin Attenuates Lipopolysaccharide-Induced Endothelial Activation and Injury-Associated Phenotypes in Human Umbilical Vein Endothelial Cells}},
author = {Jinjuan Wen and Sihao Hong and Jiaman Lai and Keyun Chen and Lingli Li and Shaoru Jiang},
journal = {Journal of Inflammation Research},
year = {2026},
month = nov,
doi = {10.2147/jir.s634490},
url = {https://doi.org/10.2147/jir.s634490},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Apigenin Attenuates Lipopolysaccharide-Induced Endothelial Activation and Injury-Associated Phenotypes in Human Umbilical Vein Endothelial Cells
AU - Jinjuan Wen
AU - Sihao Hong
AU - Jiaman Lai
AU - Keyun Chen
AU - Lingli Li
AU - Shaoru Jiang
PY - 2026
DA - 2026/11/05
JO - Journal of Inflammation Research
DO - 10.2147/jir.s634490
UR - https://doi.org/10.2147/jir.s634490
AB - Background: Sepsis represents a severe challenge in critical‑care medicine. Protecting endothelial function and alleviating microvascular inflammation and oxidative stress help reduce sepsis‑associated mortality. Apigenin, a natural flavonoid, exerts anti‑inflammatory and anti‑oxidant effects; its mechanisms against endothelial injury relevant to sepsis remain unclear. Purpose: This study combined computational biology and in‑vitro assays to explore potential targets of apigenin against lipopolysaccharide‑triggered endothelial dysfunction. Methods: Network pharmacology was performed for target screening followed by GO and KEGG enrichment. Transcriptomic profiles were analyzed. Molecular docking and 100‑ns molecular dynamics simulations predicted apigenin‑protein interactions. An LPS‑stimulated HUVECs injury model was established. qRT-PCR, ELISA, flow cytometry and fluorescent probes were used to evaluate inflammation, apoptosis, reactive oxygen species and monocyte adhesion. Results: A total of 104 intersecting targets were identified. AKT1, HSP90AA1, EGFR, ESR1 and HIF1A were potential core candidates, with PI3K‑Akt, TNF and HIF‑1 signaling possibly involved. Simulations predicted relatively stable apigenin‑protein complexes. At 40 μM, apigenin mitigated LPS‑provoked inflammatory response, oxidative stress, apoptosis and monocyte adhesion in HUVECs. Conclusion: Apigenin protects HUVECs from LPS‑induced endothelial injury possibly via multi‑target and multi‑pathway patterns. This study provides preliminary computational and in vitro evidence for further investigation of apigenin against LPS-triggered endothelial injury, with potential implications for sepsis-associated vascular damage that requires further in vivo validation.
SN - 1178-7031
ER -